EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Minimal effective dose of bedaquiline administered orally and activity of a long acting formulation of bedaquiline in the murine model of leprosy

Aurélie Chauffour iD, Nacer Lounis, Koen Andries, Vincent Jarlier, Nicolas Veziris, Alexandra Aubry

PLOS Neglected Tropical Diseases · 2023

DOI: 10.1371/journal.pntd.0011379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2023. Verfasst von Aurélie Chauffour und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), Paris, France. Hauptthemen laut MEDLINE: Diarylquinolines, Leprosy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bedaquiline (BDQ), by targeting the electron transport chain and having a long half-life, is a good candidate to simplify leprosy treatment. Our objectives were to (i) determine the minimal effective dose (MED) of BDQ administered orally, (ii) evaluate the benefit of combining two inhibitors of the respiratory chain, BDQ administered orally and clofazimine (CFZ)) and (iii) evaluate the benefit of an intramuscular injectable long-acting formulation of BDQ (intramuscular BDQ, BDQ-LA IM), in a murine model of leprosy. Methodology/Principal findings To determine the MED of BDQ administered orally and the benefit of adding CFZ, 100 four-week-old female nude mice were inoculated in the footpads with 5x10 3 bacilli of M . leprae strain THAI53. Mice were randomly allocated into: 1 untreated group, 5 groups treated with BDQ administered orally (0.10 to 25 mg/kg), 3 groups treated with CFZ 20 mg/kg alone or combined with BDQ administered orally 0.10 or 0.33 mg/kg, and 1 group treated with rifampicin (RIF) 10 mg/kg. Mice were treated 5 days a week during 24 weeks. To evaluate the benefit of the BDQ-LA IM, 340 four-week-old female swiss mice were inoculated in the footpads with 5x10 3 to 5x10 1 bacilli (or 5x10 0 for the untreated control group) of M . leprae strain THAI53. Mice were randomly allocated into the following 11 groups treated with a single dose (SD) or 3 doses (3D) 24h after the inoculation: 1 untreated group, 2 treated with RIF 10 mg/kg SD or 3D, 8 treated with BDQ administered orally or BDQ-LA IM 2 or 20 mg/kg, SD or 3D. Twelve months later, mice were sacrificed and M . leprae bacilli enumerated in the footpad. All the footpads became negative with BDQ at 3.3 mg/kg. The MED of BDQ administered orally against M . leprae in this model is therefore 3.3 mg/kg. The combination of CFZ and BDQ 10-fold lower than this MED did not significantly increase the bactericidal activity of CFZ. The BDQ-LA IM displayed similar or lower bactericidal activity than the BDQ administered orally.

Conclusion

We demonstrated that the MED of BDQ administered orally against M . leprae was 3.3 mg/kg in mice and BDQ did not add significantly to the efficacy of CFZ at the doses tested. BDQ-LA IM was similar or less active than BDQ administered orally at equivalent dosing and frequency but should be tested at higher dosing in order to reach equivalent exposure in further experiments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DiarylquinolinesLeprosyFemaleAnimalsMiceDisease Models, AnimalMice, NudeRifampinClofazimineMycobacterium lepraeAntitubercular Agents

Substanzen

bedaquilineDiarylquinolinesRifampinClofazimineAntitubercular Agents

Autor:innen und Institutionen

  • Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), Paris, France.
  • Janssen Pharmaceutica, Beerse, Belgium.
  • AP-HP. Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France.
  • APHP. Sorbonne-Université, Department of Bacteriology, Saint-Antoine Hospital, Paris, France.

ORCID-Profile: Aurélie Chauffour

Förderung

  • Janssen Research and Development

Zitieren

APA

Chauffour, A., Lounis, N., Andries, K., Jarlier, V., Veziris, N., & Aubry, A. (2023). Minimal effective dose of bedaquiline administered orally and activity of a long acting formulation of bedaquiline in the murine model of leprosy. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0011379

Vancouver

Chauffour A, Lounis N, Andries K, Jarlier V, Veziris N, Aubry A. Minimal effective dose of bedaquiline administered orally and activity of a long acting formulation of bedaquiline in the murine model of leprosy. PLOS Neglected Tropical Diseases. 2023. doi:10.1371/journal.pntd.0011379

BibTeX
@article{Chauffour2023,
  author = {Chauffour, Aurélie and Lounis, Nacer and Andries, Koen and Jarlier, Vincent and Veziris, Nicolas and Aubry, Alexandra},
  title = {Minimal effective dose of bedaquiline administered orally and activity of a long acting formulation of bedaquiline in the murine model of leprosy},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2023},
  doi = {10.1371/journal.pntd.0011379}
}
Kostenlos starten →